What are the differences between type 1 and type 2 diabetes?
Type 1 and type 2 diabetes are distinct chronic metabolic disorders with different underlying pathophysiologies, typical age of onset, clinical presentations, and management strategies.
Type 1 diabetes is an autoimmune condition characterized by T-cell–mediated destruction of pancreatic beta cells, resulting in absolute insulin deficiency. It most commonly presents in childhood or adolescence—though it can occur at any age—and typically requires lifelong exogenous insulin therapy for survival. Patients often present acutely with classic symptoms of hyperglycemia—including polyuria, polydipsia, weight loss, and fatigue—and may develop diabetic ketoacidosis (DKA) if untreated. Autoantibodies such as glutamic acid decarboxylase (GAD), insulinoma-associated antigen-2 (IA-2), and zinc transporter 8 (ZnT8) are frequently detectable.
In contrast, type 2 diabetes is primarily driven by insulin resistance in peripheral tissues (e.g., skeletal muscle, liver, adipose tissue) coupled with progressive beta-cell dysfunction and relative insulin deficiency. It is strongly associated with obesity, physical inactivity, aging, and genetic predisposition, and typically manifests in adulthood—though increasingly seen in adolescents due to rising obesity rates. Presentation is often insidious; many individuals remain asymptomatic for years and are diagnosed incidentally or during routine screening. While lifestyle modification and oral or injectable non-insulin agents (e.g., metformin, SGLT2 inhibitors, GLP-1 receptor agonists) form the cornerstone of initial management, insulin may eventually be required as beta-cell function declines over time.
Accurate differentiation is essential—not only for appropriate treatment but also for prognostication, complication risk assessment, and genetic counseling. Misclassification can lead to suboptimal therapy, avoidable complications, or unnecessary psychological burden. When clinical features overlap (e.g., lean adults with rapid progression), laboratory testing—including C-peptide levels, autoantibody panels, and clinical trajectory—helps clarify diagnosis.